Edesa Biotech(US:EDSA) Globenewswire·2026-03-31 20:20Core Insights - Edesa Biotech's CEO, Dr. Par Nijhawan, has been selected to present at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the Phase 3 results for paridiprubart in treating ARDS patients [1][3] Group 1: Presentation and Study Results - Dr. Nijhawan's presentation will focus on findings from the Phase 3 study of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome (ARDS), which leads to over three million ICU admissions globally each year [2] - The Phase 3 results include data from an initial 104 patients requiring invasive mechanical ventilation and expanded results from a broader 278-patient population, reinforcing the potential clinical benefits of paridiprubart [2] Group 2: Upcoming Events - The presentation by Dr. Nijhawan is scheduled for May 15, 2026, with an accompanying poster presentation by Edesa's research team at the summit [3] - Ted Steiner, MD, will present a full oral presentation of the Phase 3 results on May 20, 2026, during the ATS 2026 International Conference, focusing on the study's design and outcomes [4] Group 3: Product Overview - Paridiprubart is a new class of host-directed therapeutics designed to modulate the immune response against various health threats, including infectious diseases and other public health emergencies [5] - The drug works by inhibiting toll-like receptor 4 (TLR4), which is activated by various pathogens and is involved in chronic autoimmune diseases [5] Group 4: Company Background - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases, with a pipeline that includes therapies for both medical dermatology and respiratory conditions [6] - The company is developing EB06 for vitiligo and EB01 for allergic contact dermatitis, alongside its lead respiratory candidate, paridiprubart, which is supported by funding from the Government of Canada [6]